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Abstract
Background: Apoptosis-associated biomarkers are rarely studied, especially their role in predicting the
development of tuberculosis (TB) from latent TB infection and in prognostication.
Methods: Patients with TB and interferon-gamma release assay (IGRA)-positive and IGRA-negative family contacts
were evaluated to analyze changes in apoptosis-associated serum biomarkers, which included decoy receptor 3
(DcR3), prostaglandin 2 (PGE2), and lipoxin. The prognostic implications of these serum biomarkers were also
analyzed.
Results: One hundred TB patients and 92 IGRA-negative and 91 IGRA-positive family contacts were recruited. The
DcR3 and PGE2 levels decreased from the IGRA-negative group to the IGRA-positive group, and peaked in the TB
group. Lipoxin decreased to trough in the TB group. The three apoptosis serum markers and age were
independent factors discriminating active TB from latent TB infection. In active TB, older age, co-morbidity, and
higher serum DcR3 and monocyte chemotactic protein (MCP)-1 were independently associated with poorer
six-month survival.
Conclusion: Apoptosis-associated serum biomarkers change along with the status of Mycobacterium tuberculosis
infection. In close contacts with positive IGRA, high DcR3 and PGE2 and low lipoxin may increase the probability of
active TB. Older age, co-morbidity, and high DcR3 and MCP-1 levels might be important prognostic factors that
warrant further investigation.
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Background
Tuberculosis (TB) remains one of the most important
infectious diseases worldwide. According to estimates of
the World Health Organization (WHO), 3 hundred mil-
lion people were infected by Mycobacterium tuberculosis
and 30 million people died of TB from 2001 to 2010
[1,2]. In Taiwan, the incidence of TB remains high (58
per 100,000 population in 2009) [3]. To prevent further
transmissions, early diagnosis and timely treatment are
the most important strategies [4,5].
Patients infected with M. tuberculosis will develop la-
tent TB infection (LTBI), a major source of active TB
[6]. Previous studies show that about 10% of LTBI
patients will develop the active disease and this risk is
even higher in immuno-compromised hosts [7,8]. Now-
adays, LTBI is detected by tuberculin skin test and by
interferon-gamma release assay (IGRA), which measures
T-cell response against tuberculous bacilli-specific antigen
[9-11]. In particular, IGRA is reportedly more accurate in
diagnosing LTBI and as an indicator of progression to ac-
tive TB [12]. However, factors predicting the development
of active TB from LTBI remain ineffective. Active TB is
still identified mainly by traditional chest imaging and
mycobacteriologic study.
In the pathogenesis of TB, macrophages are the first-
line of defense as the TB bacilli enter the airways [13].
Phagocytosis of the bacilli is then performed by phago-
cytic antigen-presenting cells in the lungs. However, M.
tuberculosis has several mechanisms for persisting in
human tissues [14-16]. For instance, necrosis of M.
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tuberculosis-infected macrophages as the dominant form
of cell death instead of apoptosis [15,17] prevents the re-
moval of intracellular bacilli and the more efficient in-
duction of inflammation [18].
Apoptosis-associated markers, including Decoy receptor-
3 (DcR-3), lipoxin, and prostaglandin E2 (PGE2) have
rarely been investigated for discriminating active TB from
LTBI in clinical practice. Among them, DcR3 is a receptor
of the tumor necrosis factor (TNF) receptor super-family,
existing as a soluble receptor for Fas ligand, a well-known
marker in the extrinsic pathway of apoptosis, and is con-
sidered an immuno-modulator [19]. The latter two lipid
markers antagonize macrophage apoptosis in an animal
model when infected with M. tuberculosis [17,20]. Thus,
this prospective study enrolled active TB cases and IGRA-
positive and IGRA-negative family contacts and compared
serum apoptosis-associated markers to identify potentially
discriminative diagnostic and prognostic factors.
Methods
Enrolment of patients and contacts
This prospective study was conducted in a tertiary-care
referral center in northern Taiwan and its branch, a local
teaching hospital in southern Taiwan. The Research Eth-
ics Committee of National Taiwan University Hospital
approved the study (No. 9561707008). From January
2009 to June 2011, adult patients (age >20 years) with
culture- or histology-confirmed active TB were prospect-
ively identified [5]. After providing informed consent, they
received peripheral blood sampling before (TB at diagno-
sis) and one month after anti-TB treatment (TB under
treatment) for measurement of serum biomarker levels.
Family contacts with known results of an interferon-
gamma release assay (IGRA)-T-SPOT.TB (Oxford Immuno-
tech Ltd, Oxford, UK) were also enrolled. Family contacts
with negative T-SPOT.TB were considered the non-
infection group whereas family contacts with positive T-
SPOT.TB were considered the LTBI group. The contacts
received chest radiography and mycobacteriologic study
(acid-fast smear and mycobacterial culture) from 3 sputum
samples to exclude the possibility of active TB [5,21].
Patients and contacts with human immunodeficiency
virus infection and those with bleeding tendency were
excluded. Contacts with symptoms compatible with acute
infection were also excluded.
Measurements of biomarkers
Assays for apoptosis-associated markers, including lipid
markers (lipoxin and prostaglandin E [PGE]-2) and decoy
receptor (DcR)-3, cytokines (interleukin [IL]-6, IL-10,
tumor necrosis factor [TNF]-alpha, and interferon
[IFN]-gamma), chemokines (monocyte chemotactic pro-
tein [MCP]-1, macrophage inflammatory protein [MIP]-
1alpha, and MIP-1beta) were performed using serum
samples in one batch. All samples were performed in a
random order by a technician blinded to the clinical diag-
nosis. The Bioplex Multiplex Suspension Array System
(Bio-Rad Laboratories Taiwan Ltd.) [22] was used for all
chemokines and cytokines, while the ELISA method was
used for lipoxin (Biosource, California, US), PGE2, and
DcR3 (R&D Systems Europe, Abingdon, UK).
The lower limits of detection for IL-6, IL-10, IFN-
gamma, TNF-alpha, MCP-1, MIP-1alpha, MIP-1beta,
DcR3, lipoxin and PGE2 were 1.23, 1.81, 1.8, 4.72, 1.61,
1.4, 1.4, 93.7, 780, and 7.8 pg/ml, respectively. If serum
levels of a sample were below the detection range, it was
noted as half of the lower limit, i.e. 0.615, 0.905, 0.9, 2.36,
0.805, 0.7, 0.7, 46.85, 390, and 3.9 pg/ml, respectively.
Data collection
Clinical data, including age, sex, underlying co-
morbidities, history of pulmonary TB, laboratory data,
and results of acid-fast smear, mycobacterial culture, and
drug susceptibility test, as well as anti-TB treatment
course and outcomes were all recorded in a standardized
case report form. Chest imaging was reviewed and noted
as in a previous study [23]. The TB patients were
followed-up for at least six months after anti-TB treat-
ment or until death or loss to follow-up.
Statistical analysis
Serum levels of biomarkers among TB patients and fam-
ily contacts were compared. Inter-group differences were
analyzed by independent sample t test or one-way ana-
lysis of variance (ANOVA) for numerical variables, and
by chi-square test for categorical variables. Multivariate
logistic regression analysis was used to identify factors
associated with TB among TB patients and family con-
tacts with LTBI. For TB patients, survival curves were
generated using the Kaplan-Meier method and com-
pared using the log-rank test. Cox proportional hazards
regression analysis was used to identify factors asso-
ciated with six-month survival.
In the stepwise variable selection procedure, all potential
predictors were included. A two-sided p<0.05 was consid-
ered significant. The discriminative power of each bio-
marker for 1) active TB from LTBI and 2) mortality from
survival in TB patients was analyzed using the receiver op-
erating characteristic (ROC) curve and area under the
curve (AUC). The optimal cut-off value, defined as the one
with the least (1 - sensitivity)2 + (1 - specificity)2, was used
to calculate sensitivity and specificity [24]. All analyses were
performed using the SPSS (Version 13.0, Chicago, IL).
Results
During the study period, 100 TB patients (TB at diagno-
sis group), 92 IGRA-negative (non-infection group), and
91 IGRA-positive (LTBI group) family contacts were
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enrolled. The TB patients were significantly older, with
male predominance, and had higher proportion of prior
TB history and underlying co-morbidity compared to the
family contacts (Table 1). Among the 100 TB patients, 55
received follow-up blood sampling one month after anti-
TB treatment (TB under treatment group).
Between the non-infection and LTBI groups, there was
no significant difference in serum levels of biomarkers
except for MCP-1 (27.86 vs. 18.30 pg/ml, p=0.039). Be-
tween the LTBI and TB at diagnosis groups, IL-6 (2.7 vs.
64 pg/ml, p=0.018), MCP-1 (18.30 vs. 34.05, p=0.043),
DcR3 (0.64 vs. 3.97 ng/ml, p<0.001), and PGE2 (0.31 vs.
3.04, p=0.001) were significantly higher in the latter,
whereas lipoxin (3.391 vs. 1.73, p=0.008) was signifi-
cantly higher in the former. All cytokines, DcR3, lipoxin,
and PGE2 levels were not significantly different between
TB patients with malignancy and those without. Serum
levels of these markers were also not significantly differ-
ent between the TB at diagnosis and TB under treatment
groups (see online Additional file 1).
Among the four groups (i.e., non-infection group,
LTBI group, TB at diagnosis group, and TB under treat-
ment group), inflammatory cytokines, including IL-6,
TNF-alpha, and IFN-gamma decreased from the non-
infection group to the LTBI group, and then increased in
the TB patients (Figure 1A). In contrast, IL-10 showed a
continuous decreasing trend (statistically not signifi-
cant). Regarding chemokines, the trend of MCP-1 was
comparable to those of inflammatory cytokines but the
trends of MIP-1alpha and MIP-1beta increased gradually
from the non-infection group to the LTBI group to the
TB group (Figure 1B). As for apoptosis-associated mar-
kers, the trends of DcR3 and PGE2 were similar to those
of inflammatory cytokines but lipoxin had an opposite
trend (Figure 1C).
Multivariate logistic regression analysis for the LTBI
and TB at diagnosis groups revealed that age and serum
DcR3, PGE2, and lipoxin levels were independently asso-
ciated with active TB (Table 2). The results were similar
in the sub-population analysis focusing on subjects with-
out malignancy (p=0.007, p<0.001, p=0.004, p=0.017,
respectively). The AUC under the ROC curves of age,
DcR3, PGE2, and lipoxin was 0.819, 0.932, 0.859, and
0.743, respectively (Figure 2). The optimal cut-off values
were 67 years old (sensitivity 71%; specificity 87%), 1.14
ng/ml (sensitivity 87%; specificity 87%), 0.35 ng/ml (sen-
sitivity 81%; specificity 79%), and 1.82 ng/ml (sensitivity
65%; specificity 82%), respectively. A combination of
three biomarkers was used to predict the probability of
active TB disease (Table 3) and the presence of any two
provided a sensitivity of 99% and specificity of 72%.
Among the 100 TB patients, 21 (21%) died (of any
cause) during the study. Comparing the clinical character-
istics, survivors were younger and less likely to have
underlying co-morbidity. Non-survivors had higher serum
MCP-1 (p=0.012) and DcR3 (p=0.078) levels (Table 4).
Using the optimal cut-off values determined by ROC
curve analysis, the Kaplan-Meier survival curves of TB
patients according to serum MCP-1 (>28.72 vs. ≤28.72
pg/ml) and DcR3 (>2.67 vs. ≤2.67 ng/ml) levels were
plotted (Figure 3). The p values compared by log-rank
test were 0.002 and 0.004, respectively. Multivariate Cox
regression analysis revealed that age, co-morbidity, and
serum MCP-1 and DcR3 levels were independent factors
predicting six-month survival (Table 5).
Discussion
Using four groups (i.e., non-infection group, LTBI group,
TB at diagnosis group, and TB under treatment group)
of data that represent the different stages in the develop-
ment of active TB disease, the present study reveals that
apoptosis-associated biomarkers change significantly.
Levels of DcR3 and PGE2 are elevated but lipoxin is
decreased when patients have active TB compared to la-
tent infection. Combinations of the three biomarkers
and age may be useful and promising tools in clinical
practice to predict the development of active TB among
family contacts with LTBI. As for TB patients, age and
underlying co-morbidity, and serum DcR3 and MCP-1
levels at the time of diagnosis are significantly associated
with six-month survival.
Table 1 Clinical characteristics of patients with tuberculosis (TB) and family contacts by responses to interferon-
gamma release assay
IGRA-negative contacts n=92 IGRA-positive contacts n=91 TB patients n=100 p value
Age (years) 44.6 [16.9] 51.3 [15.6] 70.3 [16.2] <0.001
Male sex 32 (35%) 33 (36%) 62 (62%) <0.001
History of TB 0 0 10 (10%) <0.001
Co-morbidity 3 (3%) 7 (8%) 39 (39%) <0.001
Diabetes mellitus 2 (2%) 5 (6%) 30 (30%) <0.001
Malignancy 1 (1%) 3 (3%) 15 (15%) <0.001
Liver cirrhosis 0 0 2 (2%) 0.158
Data are no. (%) or mean [standard deviation].
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During latent infection, M. tuberculosis has several
mechanisms to protect itself from human immunity
[14-16]. One is the suppression of apoptosis of infected
macrophages because this will result in the removal of
intracellular bacilli and induction of inflammation [18,25].
M. tuberculosis also promotes its replication by inhibiting
the apoptosis of infected macrophages [18]. Macrophage
death toward necrosis instead of apoptosis is therefore a
considerably advantageous evasion mechanism of M.
tuberculosis [26].
Later, there are overwhelming systemic inflammatory
responses when active disease develops. Thus, levels of in-
flammatory cytokines decrease when subjects progress
from non-infection status to latent infection, and peak in
the active TB disease status. Although DcR3 and PGE2
levels have a similar trend, DcR3 may be a downstream
(passive) responder to inflammation-related apoptosis and
enhance the signal pathway. PGE2 plays a relatively active
role in the upstream of apoptosis [19,27,28]. In addition,
Figure 1 Histogram shows serum levels of (A) cytokines, (B)
chemokines, and (C) apoptosis-associated markers among
family contacts and patient with tuberculosis. Dx, diagnosis; Tx,
treatment; *p<0.050; **p<0.010; ***p<0.001.
Table 2 Factors significantly associated with tuberculosis
(TB) in multivariate logistic regression analysis among
contacts with latent TB infection and TB patients
Characteristics p value OR (95% C.I.)
Age, per 1 year increment 0.003 1.07 (1.02-1.11)
DcR 3, per 1 ng/mL increment <0.001 11.91 (4.03-35.17)
Lipoxin, per 1 ng/mL increment <0.001 0.39 (0.23-0.66)
PGE2, per 1 ng/mL increment <0.001 21.71 (4.66-101.28)
Abbreviations: TB, tuberculosis; DcR 3, decoy receptor 3; PGE2,
prostaglandin E2.
Figure 2 Receiver operating characteristic curves of factors
independently associated with tuberculosis among interferon-
gamma release assay (IGRA)-positive contacts and patients
with tuberculosis.
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the trend of lipoxin shows its function of antagonizing
PGE2 in apoptosis control.
After M. tuberculosis infection, macrophages are acti-
vated locally and chemokines increase, leading to a grad-
ual increase in serum MIP level from non-infection and
Table 3 Predicting the presence of tuberculosis (TB) by biomarkers
Conditions No. of matched subjects TB patients Sensitivity Specificity Positive predictive value Negative predictive value
All 59 51 51% 92% 86% 65%
Any two 127 99 99% 72% 78% 99%
Anyone 140 99 99% 59% 71% 98%
The three clinical factors included were Decoy receptor 3 (DcR3) >1.14 ng/mL, prostaglandin E2 (PGE2) >0.35 ng/mL, and lipoxin <1.82 ng /mL.
Table 4 Clinical characteristics, laboratory results,
radiologic findings and disease extent among patients
with tuberculosis (TB)
Survivors n=79 Non-survivors n=21 p value
Age (years) 68.2 [16.9] 78.3 [9.6] 0.010
Male sex 48 (61%) 14 (67%) 0.620
History of TB 6 (8%) 4 (19%) 0.120
Co-morbidity 27 (34%) 12 (57%) 0.055
Diabetes mellitus 24 (30%) 6 (29%) 0.872
Malignancy 6 (8%) 9 (43%) <0.001
Liver cirrhosis 0 2 (10%) 0.006
Diagnosis evidence 0.051
Culture positive 79 (100%) 20 (95%)
Pathology positive 0 1 (5%)
Mtb resistance
INH resistance 8 (10%) 0 0.128
RIF resistance 0 1 (5%) 0.051
Sputum AFS-positive 52 (66%) 11 (52%) 0.257
Radiographic pattern
Upper lung lesion 53 (67%) 13 (62%) 0.656
Cavitation 11 (14%) 1 (5%) 0.251
Disease extent 0.653
Pulmonary 64 (81%) 18 (86%)
Extra-pulmonary only 3 (4%) 0
Mixed 12 (15%) 3 (14%)
Blood tests
Leukocyte, (/μL) 9609 [4880] 10297 [4207] 0.542
Interleukin-6 54.9 [257.3] 98.2 [196.6] 0.408
Interleukin-10 5.6 [23.1] 4.7 [12.2] 0.814
Interferon-gamma 66.3 [472.7] 15.4 [38.9] 0.347
TNF-alpha 50.8 [375.5] 32.7 [123.7] 0.720
MCP-1 25.0 [50.1] 68.2 [116.1] 0.012
MIP-1alpha 6.1 [29.8] 1.8 [2.6] 0.210
MIP-1beta 245.4 [1274.7] 193.3 [366.2] 0.752
Decoy receptor 3 3.6 [3.8] 5.3 [3.7] 0.078
Lipoxin 1.7 [1.5] 1.7 [1.2] 0.939
Prostaglandin E2 2.9 [8.1] 3.4 [7.0] 0.793
Data are no. (%) or mean [standard deviation].
Abbreviations: MCP, monocyte chemotactic protein; MIP, macrophage
inflammatory protein; TNF, tumor necrosis factor.
Figure 3 Survival curves plotted using the Kaplan-Meier
method for patients with tuberculosis and different serum
levels of (A) MCP-1 and (B) DcR3.
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LTBI to active TB. However, MCP-1 recruits monocytes
and T lymphocytes later during the granulomatous re-
sponse [29] and may not significantly increase during
LTBI. This explains the similar trend of change as in-
flammatory cytokines.
Apoptosis-associated biomarkers, rather than inflam-
matory cytokines, are independent factors in predicting
active TB. They are of practical importance yet remain
largely unexplored. This is probably because inflamma-
tory cytokines may be influenced by multiple factors
during inflammation, whereas apoptosis-associated bio-
markers are much simpler in their pathways and have
less influence. Although apoptosis-associated markers
may be confounded by underlying co-morbidity, the as-
sociation between these markers and active TB is prob-
ably independent of underlying co-morbidity, based on
the results of the current analyses.
Among the apoptosis-associated biomarkers, DcR3
seems to be the most associated with immune cells
[19,28,30]. It has the potential to discriminate between
latent and active TB using the ROC curve analysis. From
a public health consideration, a test with high sensitivity
for predicting the development of active TB from LTBI
is most useful in preventing delayed TB diagnosis and
further transmission. If 99% of active TB cases can be
identified by DcR3 >1.14 ng/ml plus PGE2 >0.35 ng/ml,
these will be useful as screening criteria.
The six-month survival of TB patients may be con-
founded by numerous factors and is difficult to predict
simply based on characteristics at diagnosis. Many influ-
ential factors may be missed in the analysis. Nonetheless,
the results imply that baseline health conditions and ex-
tent of immune response to TB have prognostic import-
ance. DcR3 has been reported as an immuno-modulator
that skews immune response into type II macrophages
but also induces dendritic cell apoptosis [28,30]. Hence,
it may be a promising indicator of overwhelming inflam-
matory response for destruction during active TB. As a
potent recruiting signal for monocytes and T cells [31],
higher serum MCP-1 level may imply more severe
granulomatous inflammation [29]. This is the first time
that MCP-1 level in TB patients is demonstrated as a
promising tool for outcome prediction.
This study has some limitations. First, inter-group
comparison is performed in different individuals and
may be biased by individual variations. Disease processes
other than TB, like cancer, may influence serum levels of
biomarkers. Second, biomarker responses after in vitro
stimulation are not assayed. Thus, it cannot be simply
concluded that the measured levels of biomarkers in
study subjects are solely due to immune response
against M. tuberculosis. Third, the study was conducted
in a tertiary referral center and a regional teaching hos-
pital. The high prevalence of underlying co-morbidities
in TB patients may change the serum levels of biomar-
kers and lead to a relatively high mortality rate. This
limits the external generalization of the study results.
Furthermore, due to the small number of follow-up sam-
ples, firm conclusions cannot be made for the biomarker
levels after treatment.
Conclusion
In conclusion, apoptosis-associated markers significantly
correlate with the status of M. tuberculosis infection.
High DcR3 level, high PGE2 level, and low lipoxin level
may be highly sensitive criteria for identifying active TB
cases among contacts with LTBI. Prognosis is poorer in
TB patients with older age, underlying co-morbidity, and
high serum DcR3 and MCP-1 levels.
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